Oellerich M et al. Using Circulating Cell-free DNA to Monitor Personalized Cancer Therapy. Crit. Rev. Clin. Lab. Sci 2017; 54:205-218
Share This Story, Choose Your Platform!
About the Author: PFre888437
Related Posts
-
Oellerich M et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit. 2014 Apr;36(2):136-40
Oellerich M et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit. 2014 Apr;36(2):136-40
-
Schütz E et al. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med (2017) 14: e1002286
Schütz E et al. Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Med (2017) 14: e1002286
-
Beck J et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 Dec;59(12):1732-41
Beck J et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem. 2013 Dec;59(12):1732-41
-
Kanzow P et al. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation. 2014 Sep 15;98(5):e43-5
Kanzow P et al. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation. 2014 Sep 15;98(5):e43-5
Leave A Comment